Regeneron Pharmaceuticals Shares Reach 52-Week High Following Strong Q3 Results
Regeneron Pharmaceuticals (REGN) shares reached a new 52-week high following the release of robust third-quarter financial results. The company's performance was primarily driven by the strong commercial momentum of Dupixent, an asthma therapy developed in partnership with Sanofi (SNY). Market analysts have characterized the quarterly earnings as a standout performance, reflecting the continued growth and market dominance of its key therapeutic products. This positive momentum has bolstered investor confidence in Regeneron's current product portfolio and long-term growth trajectory.
Topics: earnings report pharmaceuticals stock price movement
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)